Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status.

Feng LiuZhi Rong LiuTao LiYou De LiuMeng ZhangYan XueLi Xin ZhangQian YeXiao Ping FanLei Wang

Published in: Journal of digestive diseases (2018)

The off-treatment responses to NAs differ in CHB patients with different pretreatment HBeAg status. NA withdrawal is generally safe and feasible in young patients with CHB. Long consolidation periods should be preferred in HBeAg-positive patients to achieve better durability. Benefits of cessation of NAs do not last long in HBeAg-negative CHB patients.

Keyphrases

hepatitis b virus
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
patient reported outcomes
smoking cessation
middle aged